drugset / Trial / NCT00829049

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049 ↗

Phase 4 Terminated 165 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel 0.3% in treating moderate to severe facial acne vulgaris

Timeline

Start
2007-10
Primary completion
2008-10
Completion
2008-10

Outcome

Outcome not reported

Stopped (Enrollment): “Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adapalene Other / unclassified 0.3 % —
Comparator Tazarotene Small molecule 0.1 % —

Indications